Gismo Therapeutics Inc.

[On Demand]

Gismo Therapeutics Inc. is a preclinical-stage biopharmaceutical company targeting fundamental biochemical processes that are at the root cause of neurodegenerative diseases. The company has been awarded several prestigious grants to develop its industry-leading technology. Gismo Therapeutics Inc. is developing first-in-class, disease modifying therapeutics for Alzheimer’s and Parkinson's Disease. GTC-3295, the lead products in preclinical development, has shown robust data and proof of principle in animal studies together with a very good safety profile. The company was incorporated in Delaware and has offices in Lexington, Kentucky and Queens, New York. The company was founded by Paul Gregor, Ph.D., CEO, a graduate of the Weizmann Institute of Science (Rehovot, Israel). Its Scientific Advisory Board includes Dennis Choi, M.D., Ph.D., an award-winning neurologist, Chair of Department of Neurology and Director of the Neuroscience Institute, Stony Brook University, New York.


Gismo Therapeutics Inc. is presenting as part of the NIH Innovation Zone.

Company Type:
Privately Funded Company
Company Website:
Company HQ State:
Company HQ Country:
United States
Year Founded:
Main Therapeutic Focus:
Lead Product in Development:
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided
Gismo Therapeutics Inc.